Drug Trial Radar · NCT00330460
A Randomized, Double-Blind Study to Compare the Efficacy of Treatment With Denosumab Versus Alendronate Sodium in Postmenopausal Women With Low Bone Mineral Density.
Last checked: Nov 20, 2026Latest source record: Jan 24, 2011 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,189
Actual
Start
May 2006
Primary completion
Nov 2007
Study completion Jan 2008
Sponsor
- Lead sponsor
- AmgenAmgen (AMGN)
- Sponsor type
- Industry
- First posted
- May 26, 2006
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine whether in postmenopausal women with low bone mineral density, the mean percent change in total hip BMD in subjects receiving denosumab is not less than that observed in subjects receiving alendronate sodium by more than a pre-specified non-inferiority margin.
Conditions
- Osteoporosis
- Osteopenia
Interventions
AlendronateDrug
ALN; 70 mg; oral; once weekly
DenosumabDrug
60 mg; SC; every 6 months
Primary outcomes
What the sponsor says the trial is designed to measure.
- Total Hip Bone Mineral Density Percent Change From Baseline at Month 12Time frame: 12 months
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.